Content Detail

• Content META

  Title	Q4 2024 Atea Pharmaceuticals Inc Earnings Call
  ID	7562222
  External ID	174651154
  Author
  Published Date	March 7, 2025, 11:46 a.m.
  Summary	Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Q4 2024 Atea Pharmaceuticals Inc Earnings Call Thomson Reuters StreetEvents Fri, Mar 7, 2025, 9:46 AM 16 min read In
  Tags	None
  URL	No URL
  Sentiment	Negative: 0.02672    Neutral: 0.94634    Positive: 0.02694
  Relevance	0.03167

• Content Details

  Content ID	4867468
  Key	abd71606-8aa6-40dc-a4d5-374d853ab96e
  Content	Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Q4 2024 Atea Pharmaceuticals Inc Earnings Call Thomson Reuters StreetEvents Fri, Mar 7, 2025, 9:46 AM 16 min read In This Article: AVIR -0.33% Participants Jonae Barnes; Senior Vice President, Investor Relations, Corporate Communications; Atea Pharmaceuticals Inc Jean-Pierre Sommadossi; Chairman of the Board, President, Chief Executive Officer, Founder; Atea Pharmaceuticals Inc Janet Hammond; Chief Development Officer; Atea Pharmaceuticals Inc Arantxa Horga; Chief Medical Officer; Atea Pharmaceuticals Inc Andrea Corcoran; Chief Financial Officer, Executive Vice President - Legal , Secretary; Atea Pharmaceuticals Inc Bella Camaj; Analyst; JP Morgan Andy Hsieh; Analyst; William Blair Presentation Operator Good afternoon, everybody and welcome to Atea Pharmaceuticals fourth-quarter 2024 financial results and business update conference call. (Operator Instructions) I would now like to hand the call over to Jonae Barnes, Senior Vice President, Investor Relations & Corporate Communications at Atea Pharmaceuticals. Ms. Barnes, please proceed. Jonae Barnes Thank you, operator. Good afternoon, everyone, and welcome to Atea pharmaceuticals fourth-quarter and full year 2024 financial results and business update conference call. Earlier today we issued a press release which outlines the topics we plan to discuss. You can access the press release as well as the slides that we'll be reviewing today by going to the investors section of our website at ir.ateapharma.com. With me today from Atea are our Chief Executive Officer and Founder, Jean-Pierre Sommadossi; Chief Development Officer, Janet Hammond; John Vavricka, our Chief Commercial Officer; Arantxa Horga, our Chief Medical Officer; and Chief Financial Officer and Executive Vice President of Legal, Andrea Corcoran. They will all be available for the Q&A portion of today's call. Before we begin the call and as outlined on slide 2, I would like to remind you that today's discussion will contain forward-looking statements that involve risk and uncertainties. These risks and uncertainties are outlined in today's press release and in the company's recent filings with the Securities and Exchange Commission, which we encourage you to read. Our actual results may differ materially from what is discussed on today's call. With that, I'll now turn the call over to Jean-Pierre. Jean-Pierre Sommadossi Thank you, Jonae. Good afternoon, everyone, and thank you for joining us. I will begin on slide 3. We made significant progress last year advancing our HCV program with the regimen of bemnifosbuvir and ruzasvir. In December, we reported positive results from our global Phase 2 trial, which demonstrated the 98% cure rate in the primary efficacy analysis, with a short eight week treatment. The very high SVR rate demonstrates the robust potency across HCV genotypes. We believe our regimen, if approved, has the opportunity to become a best-in-class hepatitis C treatment and disrupt the global HCV market of approximately $3 billion in annual net sales. The very positive Phase 2 results helped to support a successful end of Phase 2 meeting with the FDA, which occurred this past January. In addition to the substantial progress that we have -- in addition to the substantial clinical progress, business updates include the recent step we have taken to further enhance shareholder value. This includes the retention of Evercore, a global investment bank, to assist us in the exploration of strategic partnership related to our Phase 3 HCV program. We also took cost cutting actions to enhance efficiency in the management of infrastructure expenditures, which Andrea will discuss in further details. In February, we appointment -- we announced the appointment of a new independent director, Arthur Kirsch, who brings decades of financial and strategic advisory experience to our board of director. Moving to slide 4. Based upon the encouraging results to date, together with the successful outcome of the FDA meeting, we are initiating the global Phase 3 program evaluating the regimen of bemnifosbuvir and ruzasvir and expect enrollment to begin next month. We believe that our Phase 3 program is de-risked with a compelling value proposition. Furthermore, robust Phase 2 results for antiviral therapies have historically led to a high probability of success in Phase 3 studies. In addition, we will be showing today results from a multi-scale modeling approach that confirm the high likelihood of success of our Phase 3 program. With $454.7 million of cash, cash equivalent and marketable securities of December 31, 2024, we are in a strong financial position to execute and complete our Phase 3 HCV program as we anticipate our cash runway will expand into 2028. Moving to slide 5. HCV's continued to be a significant global healthcare issue despite the availability of direct acting anti-viral for the past decade. The unrelenting high rate of HCV infections, which is outpacing the stagnant number of patients being treated, underscored the need for a new, differentiated, and optimized therapy. I would like to point out that we still have a very large number of untreated HCV patients of between 2.4 to 4 million in the United States. And let's not forget that in the United States, 70% of liver cancer is a consequence of HCV disease progression. Therefore, the lack of treatment of these HCV patients has a profound impact not only on patients' lives, but also with the associated healthcare hospitalization cost. On slide 6, the large burden of untreated HCV disease translates into a large, untapped commercial opportunity. Currently in the United States, out of the 160,000 new infections every year, only approximately 100,000 patients are treated. Last year, for example, the US treated patients resulted in approximately $1.5 billion net sales, and globally, the market continues to approximately $3 billion. We believe that the best in class profile of our regiment, together with the anticipated removal of access barrier and future government initiatives, can dramatically expand the number of patients curing in the United States from this severe viral disease. With that, I will now turn the call over to Janet to review the profile of our regiment and the global Phase 3 program. Janet. Story Continues Janet Hammond Thanks, Jean-Pierre. On slide 7, our potential best-in-class regimen is the only one that combines the required attributes to suit today's HCV patients. Our regimen combines bemnifosbuvir, which is the most potent nucleotide for HCV yet to have been developed, and ruzasvir, which is a highly potent HCV NS5A inhibitor. This regimen is differentiated from the approved treatments. It offers a highly potent pan-genotypic therapy, with a short treatment duration, along with a low potential for drug-drug interactions, and can be taken with or without food. All these attributes address the needs of the prescriber and the patient. Slide 8 illustrates that only our regimen has a preferred drug-drug interaction profile. Since approximately 80% of HCV patients are taking concomitant medication, the drug-drug interaction profile of HCV therapies is of particular importance to both patients and prescribers for ease of use. As detailed on this slide, the regimen of bemnifosbuvir and ruzasvir has the cleanest drug-drug interaction profile, with commonly prescribed medications such as oral contraceptives, statins, and proton pump inhibitors. On slide 10, I'm excited to share an update for our Phase 3 program. In January, we had a successful end of Phase 2 meeting with the FDA. Following the meeting and at the request of the FDA, we submitted the final Phase 3 protocol, which also will be submitted to other regulatory agencies. We're currently in the process of opening up clinical sites, and we're targeting over 250 sites worldwide. As JP stated earlier in the presentation, we are initiating the Phase 3 program and expect enrollment to begin in April. On slide 11. Our global HCV Phase 3 program consists of two randomized open label Phase 3 trials, comparing the regimen of bemnifosbuvir and ruzasvir to the regimen of sofosbuvir and velpatasvir in patients with chronic HCV infection. Each trial will enroll approximately 800 treatment-naive patients, both with and without compensated cirrhosis. Patients will be stratified by genotypes and cirrhosis status. And patients with HIV coinfection will be allowed. For non-cirrhotic patients, which represent more than 90% of patients in the US, eight weeks of bemnifosbuvir and ruzasvir will be compared with 12 weeks of sofosbuvir and velpatasvir. For cirrhotic patients, 12 weeks of bemnifosbuvir and ruzasvir will be compared with 12 weeks of sofosbuvir and velpatasvir. The primary endpoint for both trials encompasses sustained virologic response 12 weeks after treatment, or SVR12, in each arm, and is HCV RNA less than the lower limit of quantitation 24 weeks from the start of treatment. Measurement of 24 weeks from the start of treatment is selected to ensure the primary endpoint occurs at the same relative time point from the start of treatment in all patients. With that, I'll now turn the call over to Arantxa for a review of the global Phase 2 HCV study results. Arantxa Horga Thank you, Janet. On slide 12, I would like to remind you that our global Phase 2 study was a single arm of 550 milligram for bemnifosbuvir with 180 milligrams of ruzasvir once daily for eight weeks. This Phase 2 trial involved 275 treatment-naive patients chronically infected with HCV, including patients with compensated cirrhosis. In the study, we had two efficacy populations. The primary efficacy endpoint was in the treatment adherent population. A secondary efficacy analysis assessed SVR12 in the same population, but also included non-adherent patients. Of note, we had 17% of patients who did not take the study medication or were non-adherent in our Phase 2 study, and this non-adherent rate is similar to what was reported in our third-party market research. Moving to slide 13, the primary efficacy endpoint demonstrates a 98% SVR12 rate in all adhering patients after eight weeks of treatment, and a 95% SVR12 rate was achieved in patients regardless of treatment adherent. This patient population also included cirrhotic patients where the SVR12 was 88%. This cirrhotic patients on treatment bio kinetics was slower, but it is important to note that 100% bio clearance was achieved at the end of treatment. Therefore, we can expect that 12 weeks of treatment in cirrhotic patients should lead to very high SVR rates. Slide 14 shows that the overall non-cirrhotic treatment adhering population, SVR12 was almost 100%, with only one failure in 179 patients. In genotype 3, it was 100%, which is a genotype historically hard to treat. The robust potency and drug forgiveness was demonstrated in non-cirrhotic patients regardless of drug adherence, with the regimen achieving 97% SVR 12 in the overall population and 98% in genotype 3, even with 20% of these patients being non-adherent. On slide 15, the regimen of bemnifosbuvir and ruzasvir was generally safe and well tolerated, with no drug-related severe adverse events or premature treatment discontinuations. Similarly, there were no trends observed in adverse events or safety laboratory parameters. Let's now review new modeling data on slide 16. The Phase 2 data was further evaluated in a multi-scale model of HCV infection and treatment to confirm the effectiveness of bemnifosbuvir and ruzasvir. A similar approach has been previously validated and published to evaluate other BEM regimens against HCV. In this model, the population estimate for the time to achieve HCV RNA, less than the lower limit of quantification in the plasma, was approximately 12 to 16 days, while the corresponding time to achieve cure was approximately seven to eight weeks. Therefore, this model provides further support for a high likelihood of success for the regimen being evaluated in Phase 3, with durations of eight weeks in non-cirrhotic patients and 12 weeks in cirrhotic patients. I will now turn the call over to Andrea to discuss Atea's financials. Andrea Corcoran Thank you, Arantxa. As Jonae mentioned, earlier today, we issued a press release containing our financial results for the fourth quarter and full year 2024. The statement of operations and balance sheet can be found on slides 18 and 19. In 2024, R&D expenses declined quarter over quarter but increased year over year in 2024. The full year increase was primarily driven by higher 2024 external spend related to our COVID-19 Phase 3 SUNRISE-3 trial, as well as our Phase 2 HCV trial. For G&A, expenses in 2024 and 2023 were similar quarter over quarter and year over year. Interest income quarter over quarter and year over year decreased due to lower investment balances. In 2025, substantially, all our external R&D spend will be related to the advancement of our Phase 3 program. As Jean-Pierre mentioned, at year end 2024, our cash, cash equivalent, and marketable securities balance was $454.7 million. Continuing our strong financial discipline, we protect cash guidance runway into 2028. Moving to slide 20. As noted in our press release today, we announced a reduction of our workforce by approximately 20%-25% in early January. This action is intended to enhance efficiency in the management of infrastructure expenditures, and is expected to result in a cost savings of approximately $15 million through 2027. Additionally, we also announced that Arthur Kirsch has joined our Board of Directors. His extensive financial and strategic advisory experience will further strengthen the Atea Board as we advance our strategic priorities. We believe that Arthur's proven track record of executing and overseeing transactions will be invaluable as we pursue opportunities to enhance shareholder value. I'll now turn the call back over to Jean-Pierre for closing remarks. Jean-Pierre Sommadossi Thank you, Andrea. In closing, we believe that our global Phase 3 HCV program is de-risked with a high compelling value proposition. This is based on substantial preclinical and mostly clinical data, a well characterized regulatory password, optimized manufacturing processes, a durable multibillion-dollar market, and a long path on runway. We believe that the regiment of bemnifosbuvir and ruzasvir, with its potential best-in-class profile for the treatment of hepatitis C if approved, provides an opportunity to become the most prescribed treatment and disrupt the global hepatitis C market of approximately $3 billion in annual net sales. Before opening the call to your questions, I would like to thank our talented and dedicated Atea employees. Our team of relentless pursuit of excellence drive our dedication to advancing all antiviral therapeutics for patients worldwide affected by severe viral diseases. With that, I would turn the call back over to the operator. Question and Answer Session Operator (Operator Instructions) One moment while we compile our Q&A roster. Bella Camaj, JP Morgan. Bella Camaj Hi, this is Bella on for Eric. Just two questions from us here. First, following your meeting with the FDA, are there any specific callouts that they've guided for in the Phase 3 trial design? And then second, what can we expect in terms of the scope of your Phase 2 read out later this half? Jean-Pierre Sommadossi Janet, you want to address the first one? And then Arantxa will address the second question. Janet. Janet Hammond Thank you, JP. Yeah. So with regards to our meeting with the FDA, no, I don't think really any specific callout. They are fully aligned with our approach of going forward with two open label Phase 3 trials. I think it's somewhat unconventional to run open label trials, but I think given the circumstances of the different properties of the drugs in the population that we are studying, this is completely in agreement with them. And they didn't really have any substantive comments around the conduct of the trial. Jean-Pierre Sommadossi Arantxa. Arantxa Horga Yes, I think, the question from Bella was about the Phase 2 read out. So we're expecting to present data this summer at [AASLD] in May. And so you'll have additional data there in terms of the (inaudible) on safety, and all the other details of the protocol of the study. Bella Camaj Great, thank you. Operator Thank you. And one moment for our next question. Andy Hsieh, William Blair. Andy Hsieh Oh great. Three questions from us, if you don't mind. One is on the trial design for the Phase 3 program. I'm curious if you have an estimated number of cirrhotic patients across those two trials. Are they going to be strictly controlled, or this is kind of an estimation based on global and US epidemiology? So that's question number one. Jean-Pierre Sommadossi Let's do by one question at a time, if you don't mind. So Janet, address those question please. Janet Hammond Yes. So there are estimates. We have target numbers of cirrhotic patients that we'd like to see enroll in the trial. But the number of cirrhotic patients, I think, generally worldwide, has declined with the advent of direct acting antiviral therapies. I think particularly so in the US they're harder to find than I think they were when the earlier direct acting antiviral trials were conducted. But we do anticipate seeing somewhere in the order of just north of 10%, probably in our trial, and that's what we're aiming for. Andy Hsieh I see. Is there an ability for you to adjust that number, if you're seeing maybe a little bit lower or a little bit higher -- Janet Hammond Yes, I think so -- Andy Hsieh As the trial originally -- Janet Hammond Yes, I think so. As I said, we're having -- we're setting targets, not absolute numbers. So we do have some flexibility in there, and obviously, if we can achieve more and get greater experience, I think that will be important, but I don't think there are absolute requirements around that. We want to have sufficient patients enrolled to be able to justify having that population in our label. But I think we're certainly going to do the best we can to have enough, but there is flexibility there. Andy Hsieh That's helpful. Second question has to do with the modeling, which is very unique on slide 16. So I'm curious, if you were to plot this with Epclusa, well would you expect that those two lines to be right-shifted for Epclusa across the -- Jean-Pierre Sommadossi You're wrong. Andy Hsieh Non-cirrhotic [adherent] population? Jean-Pierre Sommadossi This model has been developed by Dr. [Alan Pearson] from Los Alamos. And please check the recent publications with other direct antiviral for HCV. Andy Hsieh Okay. Yeah, that's helpful. Okay, that's -- actually, sorry for the confusion. There's just two questions from us, but thanks for your input. Jean-Pierre Sommadossi Okay. You're very welcome. Thank you for the questions. Operator (Operator Instructions) I'm showing no further questions, and I would like to hand the conference back over to Jean-Pierre for closing remarks. Jean-Pierre Sommadossi Thank you for all of you for joining our fourth-quarter 2024 earning conference call. And thank you for your continued support. Operator This concludes today's conference call. Thank you for participating, and you may all disconnect. Everyone, have a great day. View Comments Terms and Privacy Policy Your Privacy Choices CA Privacy Notice More Info Recommended Stories
  Content Reference URL	None

• Publisher

  None

• Data Source

  Data Source Name	Yahoo Finance News
  Data Source Type	news
  Data Source URL	https://finance.yahoo.com/
  Description	Yahoo! Finance is a media property that is part of the Yahoo! network. It provides financial news, data and commentary including stock quotes, press releases, financial reports, and original content. It also offers some online tools for personal finance management.
  Weight	10